Cullinan Therapeutics (CGEM) to Release Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Cullinan Therapeutics to post earnings of ($0.80) per share for the quarter.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Performance

Cullinan Therapeutics stock opened at $7.88 on Thursday. Cullinan Therapeutics has a 1 year low of $6.85 and a 1 year high of $19.89. The firm’s 50-day moving average is $8.11 and its 200-day moving average is $8.43. The company has a market cap of $465.00 million, a P/E ratio of -2.71 and a beta of -0.08.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. UBS Group dropped their price target on Cullinan Therapeutics from $30.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday, May 12th. HC Wainwright restated a “buy” rating and set a $33.00 price objective on shares of Cullinan Therapeutics in a research note on Wednesday, April 16th. Finally, Stifel Nicolaus started coverage on Cullinan Therapeutics in a research note on Wednesday, June 11th. They issued a “buy” rating and a $22.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $30.00.

Institutional Investors Weigh In On Cullinan Therapeutics

Large investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new stake in shares of Cullinan Therapeutics in the first quarter worth approximately $618,000. Jane Street Group LLC increased its stake in shares of Cullinan Therapeutics by 145.9% in the first quarter. Jane Street Group LLC now owns 34,396 shares of the company’s stock worth $260,000 after acquiring an additional 109,413 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cullinan Therapeutics during the first quarter worth $163,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.